GLXO's 2QFY22 performance was better than our expectations due to a healthy revival in the anti-infective/derma segment, coupled with improved operating leverage. In particular, Augmentin and Calpol regained their place among the top five brands in the Indian Pharmaceuticals Market (IPM). The...